The First Tissue Regeneration Therapy For Short Bowel Syndrome (SBS)
*The Eclipse XL1 is currently under development and not available for clinical use.
The Eclipse XL1
A revolutionary approach to the treatment of Short Bowel Syndrome (SBS).
Short Bowel Syndrome (SBS) is a devastating condition in which patients struggle to absorb sufficient and life-sustaining nutrients as a result thereof intestinal resection. Designed, developed, and driven to market by the leading experts in Short Bowel Syndrome (SBS), the Eclipse XL1 is pioneering the next generation of treatment as the world’s first tissue regeneration therapy.
Short Bowel Syndrome (SBS) Today
No restorative solution and a patient population desperate for help.
Without a restorative solution available, patients with Short Bowel Syndrome (SBS) are reliant on life-sustaining solutions such as Total Parenteral Nutrition (TPN), Drug Therapies, and Surgical or Intestinal Transplantation.
Total Parenteral Nutrition (TPN)
• Lifelong Intravenous (IV) feeding and nutritional support
• Frequent hospitalizations for venous catheter-associated complications (infections, displacement, etc.)
• Toxicity often leading to end-stage liver disease
Drug Therapy (Teduglutide Injections)
• Daily injections
• Minimal improvement in
absorption (max 20%)
• TPN/IV nutrition still required
Surgery and Intestinal Transplantation
• May not increase nutrient absorption
• May require lifelong immunosuppression drugs
• High risk of infection, rejection, death
Proudly Partnered With
Our commitment to patient-centered innovation is driven by our partnerships with some of the leading healthcare organizations in the world. Eclipse Regenesis is proudly partnered with Boston Children’s Hospital, Cincinnati Children’s, UCLA Health, and Stanford Medicine. Together with our partners, we continue to pioneer the next generation of treatment for patients with Short Bowel Syndrome (SBS).